Teva Shares Rally, Forecast 'Very Strong Launch' for Long-awaited Ajovy Migraine Treatment

The company added that it expected to launch its generic version of the best-selling EpiPen allergy treatment in the current quarter

Send in e-mailSend in e-mail
Teva Pharmaceutical Industries Ltd.'s headquarters in Jerusalem, Israel, September 19, 2011
Teva Pharmaceutical Industries Ltd.'s headquarters in Jerusalem, Israel, September 19, 2011Credit: Bloomberg

Comments